Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2014 | 03-2014 | 12-2013 | 09-2013 | 06-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 18,126 | 16,649 | 15,696 | 8,254 | 4,636 |
| TOTAL | $18,126 | $16,649 | $15,696 | $8,299 | $4,729 |
| Non-Current Assets | |||||
| PPE Net | 27 | 28 | 30 | 32 | 27 |
| Intangibles | 3,919 | 4,087 | 4,255 | 4,423 | 4,590 |
| Other Non-Current Assets | 27 | 27 | 27 | 27 | 27 |
| TOTAL | $3,973 | $4,142 | $4,312 | $4,481 | $4,644 |
| Total Assets | $22,099 | $20,791 | $20,008 | $12,780 | $9,373 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 480 | 725 | 349 | 203 | 65 |
| Accrued Expenses | 104 | 61 | 61 | 160 | 237 |
| TOTAL | $817 | $835 | $513 | $543 | $414 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,303 | 5,436 | 12,867 | 3,515 | 2,612 |
| TOTAL | $1,303 | $5,436 | $12,867 | $3,515 | $2,612 |
| Total Liabilities | $2,119 | $6,271 | $13,380 | $4,057 | $3,026 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 176,638 | 173,126 | 172,450 | 139,974 | 128,625 |
| Common Shares | 177 | 173 | 160 | 140 | 129 |
| Retained earnings | -153,362 | -152,718 | -146,051 | -129,453 | -124,901 |
| TOTAL | $19,980 | $14,520 | $6,629 | $8,723 | $6,347 |
| Total Liabilities And Equity | $22,099 | $20,791 | $20,008 | $12,780 | $9,373 |